U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07951606) titled 'Safty and Efficacy of KH658 in Subjects With Diabetic Retinopathy' on Nov. 16.

Brief Summary: KH658 is a adeno-associated virus (AAV) vector-based gene therapy for suprachoroidal space injection. The long-term, stable therapeutic protein after one time injection for DR could potentially reduce the treatment burden and maintain visual acuity and retinal anatomical stability

Study Start Date: Feb., 2027

Study Type: INTERVENTIONAL

Condition: Diabetic Retinopathy

Intervention: GENETIC: KH658 Dose 1

KH658 Dose 1 suprachoriodal single injection

GENETIC: KH658 Dose 2

KH658 Dose 2 suprachoriodal single injection

DRUG: Ranibizumab...